Cardio-Oncology and Cardio- Oncological Prevention
Osuna Iturrios Daniela
 
 
 
Combination therapy often ampli!es cardiotoxicity, and radiotherapy can also cause heart problems, particularly "hen combined "ith chemotherapy
 
• $oday % s oncologists must be fully a"are of cardiovascular risks to avoid or prevent adverse cardiovascular eects, and cardiologists must no" be ready to assist oncologists by performing evaluations relevant to the choice of therapy
There is a need for cooperation beteen these to areas and for the develop!ent of a novel discipline" hich could be ter!ed
CA#D$O-ONCO%O&' O# ONCO- CA#D$O%O&'.
 
 
• $he discovery of ne" biomarkers to identify patients at a high risk for the
development of these complications is a high priority
• &uidelines for cancer treatment that take cardiologic conditions into
account are currently lacking and need to be developed
• Identi!cation of ne" compounds such as antioxidants and endothelial- or cardiomyocyte-protective agents that can prevent cardiotoxicity
• 'ssessment of cardiotoxicity should become part of phase I trials to
develop agents "ith less risk
CONC%()$ON
• $here is a need to train a generation of (cardio- oncologist) or (onco-cardiologist) investigators and clinicians to overcome these communication gaps